Intranasal foralumab can modulate a number of immune cell types in people with non-active SPMS, developer Tiziana Life ...

The agreement will allow Enigma to use its PET imaging tracer PMI04 to visualize microglia activity in neurodegenerative ...

Columnist Ahna Crum relates her years-long struggle with avascular necrosis, the reason she has a "bone to pick" with ...

PTD802 is a selective inhibitor of the GPR17 receptor and is made to restore myelin, a process known as remyelination, in ...

The Accelerated Cure Project for Multiple Sclerosis launched a new website to better support caregivers of people with MS.

The U.S. Food and Drug Administration (FDA) has added a new boxed warning to the prescribing information for glatiramer acetate, an approved injection therapy for relapsing forms of multiple ...

Tech company Century Health will organize and clean Nira Medical's datasets from more than 3,000 people with MS to aid ...

Switching therapies is a common part of multiple sclerosis management and may be considered for several reasons.

Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, like those done in MS, uses 60% less gadolinium and ...

TG Therapeutics said it is working to develop a subcutaneous (under-the-skin) version of relapsing MS therapy Briumvi.

Enigma Biomedical has entered into an agreement with Neuraly to use its PET imaging tracer PMI04 to visualize microglia activity in people with neurodegenerative diseases such as multiple ...

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.